Adelaide Proteomics Centre technology to identify proteins; used in cancer and multiple sclerosis research
The highly sensitive and accurate technologies at Adelaide Proteomics Centre are used to identify and quantify and identify thousands of proteins in biological samples.
The Adelaide Proteomics Centre in the school of molecular and biomedical science at Adelaide University offers researchers from all biological sciences a state-of-the-art service in mass-spectrometry-based identifying of proteins.
Proteomics is the study of the proteome: all the proteins expressed in a cell. Proteomics used techniques to quantify and identify thousands of proteins in biological samples. These samples included cerebrospinal fluid, tissue biopsies or cell cultures.
The Adelaide centre has developed highly sensitive and accurate technologies for comparative proteomics experiments.
Working with SAHMRI (South Australian Health and Medical Research Institute), the team at Adelaide Proteomics Centre has used LC-MS (liquid chromatography–mass spectrometry) as the primary application in discovery proteomics and phosphoproteomics, with a focus on blood cancers and stroke research.
The Adelaide Proteomics Centre was also a key part of Adelaide University’s lead role in the MS (Multiple Sclerosis) Australia Proteomics Platform, a major national combined research project by three Australian universities and the Sir Charles Gairdner Hospital in Western Australia. This aimed to discover the proteins involved in the development and pathology of multiple sclerosis.
It is the first of its kind in Australia and one of the first of its kind in the world. Most research to date has focussed on investigating limited specific molecules and this has resulted in slow progress towards understanding of the pathogenesis of multiple sclerosis. The platform started in 2010 and was funded over four years through the Australian Research Council’s linkage projects funding in partnership with MS Research Australia.
This platform aimed to develop state-of-the-art proteomics technologies for the Australian multiple scelerosis research community and used the technology to identify specific molecular changes in the central nervous system proteome that correlate with different stages of disease in multiple sclerosis. The result of this research was likely to lead to the identifying new proteins that could be targeted to develop therapies and diagnostics for multiple sclerosis.
